Aline Kidikian
Family · Newport Beach, CANPI 1962172106
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 275 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,295, more than ten times the $19 reported in 2021. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$709
- Boehringer Ingelheim$593
- Otsuka America Pharmaceutical, Inc.$541
- Ardelyx, Inc.$522
- Vifor Pharma, Inc.$409
- Bayer$378
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,960100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 31 | $709 |
| Boehringer Ingelheim | 38 | $593 |
| Otsuka America Pharmaceutical, Inc. | 23 | $541 |
| Ardelyx, Inc. | 24 | $522 |
| Vifor Pharma, Inc. | 17 | $409 |
| Bayer | 18 | $378 |
| Calliditas Therapeutics US Inc. | 13 | $308 |
| Novartis | 13 | $287 |
| Aurinia Pharma U.S., Inc. | 12 | $258 |
| Mallinckrodt Hospital Products Inc. | 9 | $258 |
| Fresenius USA Marketing, Inc. | 11 | $257 |
| OPKO Pharmaceuticals, LLC | 11 | $206 |
| Novo Nordisk | 9 | $183 |
| Amgen | 6 | $161 |
| Apellis Pharmaceuticals, Inc. | 7 | $149 |
| Recor Medical Inc | 4 | $111 |
| Merck | 4 | $76 |
| AbbVie | 3 | $65 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Scpharmaceuticals Inc. | 2 | $48 |
| Viiv Healthcare Company | 2 | $43 |
| Johnson & Johnson | 2 | $39 |
| Travere Therapeutics, Inc. | 2 | $34 |
| Cycle Pharmaceuticals Inc | 1 | $32 |
| GSK | 1 | $31 |
| Idorsia Pharmaceuticals US Inc | 1 | $31 |
| Hologic Sales And Service, LLC | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Akebia Therapeutics Inc | 1 | $24 |
| Sanofi | 1 | $23 |
| Theratechnologies Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Indivior Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$5,974 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 166 | $173,605 |
| LokelmaSodium Zirconium Cyclosilicate | 32 | $32,894 |
| JardianceEmpagliflozin | 18 | $21,431 |
| DapagliflozinDapagliflozin Propanediol | 28 | $18,884 |
| OzempicSemaglutide | 16 | $17,405 |
| KerendiaFinerenone | 11 | $12,456 |
| Sevelamer Carbonate | 28 | $4,856 |
| Nebivolol Hcl | 36 | $2,799 |
| Febuxostat | 17 | $2,243 |
| Olmesartan Medoxomil | 61 | $1,642 |
| Nifedipine ErNifedipine | 28 | $1,273 |
| Calcitriol | 55 | $909 |
| Midodrine Hcl | 11 | $760 |
| Losartan Potassium | 99 | $736 |
| Hydralazine Hcl | 41 | $733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $709 | $206,499198 claims |
| Boehringer IngelheimJardiance | $593 | $21,43118 claims |
| Novo NordiskOzempic | $183 | $17,40516 claims |
| BayerKerendia | $378 | $12,45611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Newport Beach
- Carol ChowNewport Beach$129K
- Anisa MunshiNewport Beach$120K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.